治疗药物监测中茄啶分析揭示罕见CYP2D6慢代谢型基因型:一例病例报告
本文报道一例曾被基因分型为CYP2D6*1/*1(正常代谢型)的患者,在治疗药物监测中通过检测马铃薯来源的茄啶及其CYP2D6依赖性代谢物4-羟基茄啶,提示为CYP2D6慢代谢型(PM)。扩展基因分型面板复检后确认为罕见基因型CYP2D6*7/*7。该案例表明,茄啶与4-羟基茄啶半定量检测可作为基因分型的补充工具,用于筛选应接受基因分型的患者。
要点
- 茄啶和4-羟基茄啶半定量检测可高准确度预测CYP2D6慢代谢型。
- 该检测可识别标准基因分型面板未覆盖的罕见变异。
- 该工具可减少临床实践中识别CYP2D6慢代谢型所需基因分型人数。
核心结论
- 茄啶和4-羟基茄啶半定量分析可作为基因分型的补充工具,用于识别应接受CYP2D6基因分型的患者。
- 该检测能发现标准基因分型面板未包含的罕见CYP2D6变异。
研究设计与样本
- 病例报告:一例既往基因分型为CYP2D6*1/*1并解读为正常代谢型的患者。
- 在常规治疗药物监测中检测茄啶和4-羟基茄啶信号,提示CYP2D6慢代谢型。
- 随后使用扩展基因分型面板复检,确认罕见基因型CYP2D6*7/*7。
主要发现
- 患者在使用标准剂量的CYP2D6底物奋乃静和阿立哌唑期间有副作用史。
- 治疗药物监测样本中茄啶和4-羟基茄啶信号指示CYP2D6慢代谢型。
- 扩展基因分型面板复检揭示CYP2D6*7/*7,编码慢代谢型。
关键数值与推荐
- CYP2D6参与20-25%常用临床药物的代谢。
- 5-10%的高加索人为CYP2D6无酶活性变异等位基因的纯合携带者,归类为慢代谢型。
- 近期研究显示茄啶和4-羟基茄啶半定量检测预测CYP2D6慢代谢型具有极佳准确度。
临床怎么用
- 在常规治疗药物监测中纳入茄啶和4-羟基茄啶半定量检测,作为基因分型的补充工具。
- 对检测提示CYP2D6慢代谢型的患者,应选择进行基因分型,包括扩展面板以覆盖罕见变异。
局限性
- 本文为单例病例报告,结论需在更大样本中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of 20-25% of commonly used clinical drugs. Between 5 and 10% of Caucasians are homozygous carriers of variant alleles encoding no CYP2D6 enzyme activity, who are classified as poor metabolizers (PMs). Increased risk of supratherapeutic concentrations and adverse effects of CYP2D6 substrates have been reported in PMs during standard recommended dosing. Recently, semiquantitative measurements of the potato-derived compound solanidine and its CYP2D6-dependent metabolite 4-hydroxysolanidine have been shown to predict CYP2D6 PMs with excellent accuracy. We have therefore implemented these measurements as part of our routine therapeutic drug monitoring practice to provide a recommendation for genotyping. Here we report a case where solanidine and 4-hydroxysolanidine signals in a therapeutic drug monitoring sample indicated CYP2D6 PM status in a patient who had previously been genotyped as CYP2D6 *1/*1 and interpreted as a normal metaboliser. The patient had a history of side effects during use of the CYP2D6 substrates perphenazine and aripiprazole at standard doses. Upon reanalysis with an extended genotyping panel, a rare CYP2D6 genotype (CYP2D6*7/*7) encoding PM status was revealed. The report shows the clinical value and feasibility of analysing solanidine and 4-hydroxysolanidine as part of routine therapeutic drug monitoring to identify patients predicted to be CYP2D6 PMs and who should be selected for genotyping, including patients with rare variants not included in standard genotyping panels. Solanidine and 4-hydroxysolanidine semiquantitation can be used as a complementary tool to genotyping and substantially reduce the number-needed-to-genotype for identification of CYP2D6 PMs in clinical practice.
引用
- Størset E, Wollmann BM, Larne SG, et al. Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: A case report. Br J Clin Pharmacol. 2025. PMID: 40744734. doi:10.1002/bcp.70184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。